Run Wang, MD
Urology · Houston, TXNPI 1386677268
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $122,475 of the $194,738 with a category attached, or 62.9%. 24 manufacturers reported payments, led by Teleflex LLC at 43.7% of the total. Reporting peaked in 2023 at $94,261 and has fallen 97.0% since, to $2,866 in 2025. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 388 payments — averaging $501.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$85K
- Boston Scientific$78K
- Neotract Inc.$13K
- Coloplast$8K
- Endo Pharmaceuticals Inc.$6K
- Teleflex Medical Trading (shanghai) Co., Ltd.$3K
- plus $2K from 18 others
What the payments were for
- Consulting fees$44,12423%
- Speaking & faculty fees$122,47563%
- Grants$1,5001%
- Travel & lodging$11,6466%
- Food & beverage$11,3266%
- Education$3,6672%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 59 | $85,130 |
| Boston Scientific | 132 | $78,301 |
| Neotract Inc. | 8 | $13,372 |
| Coloplast | 87 | $7,676 |
| Endo Pharmaceuticals Inc. | 38 | $5,570 |
| Teleflex Medical Trading (shanghai) Co., Ltd. | 1 | $2,549 |
| Angiodynamics, Inc. | 29 | $919 |
| Axonics, Inc. | 8 | $396 |
| Axogen | 2 | $210 |
| Antares Pharma, Inc. | 2 | $100 |
| Astellas Pharma US Inc | 6 | $94 |
| Bayer | 1 | $83 |
| Stryker | 1 | $46 |
| AbbVie(2 entities) | 3 | $43 |
| Olympus America Inc. | 1 | $42 |
| Johnson & Johnson(2 entities) | 2 | $28 |
| Ambu Inc. | 1 | $26 |
| Innovation Technologies Inc | 1 | $25 |
| Cook Medical LLC | 1 | $25 |
| ABC Home Medical Supply, Inc. | 1 | $24 |
| Urogen Pharma, Inc. | 1 | $21 |
| Urovant Sciences Inc | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$70,810
- UroLift System$29,679
- AMS$25,696
- rezum Generator$9,718
- GENERAL BPH$5,851
- TITAN$5,220
- XIAFLEX$4,992
- AMS 700 CXR RTE KIT$3,000
- GENERAL ERECTILE DYSFUNCTION$1,610
- AMS 800 Artificial Urinary Sphincter$171
- Axonics r-SNM System$118
- Bulkamid$116
- Axonics$116
- Nanoknife$111
How this compares
$194,738 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 14 | $9,534 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 41 | $597 |
| Tamsulosin Hcl | 51 | $436 |
| Finasteride | 44 | $279 |
| Cephalexin | 33 | $166 |
| Levofloxacin | 29 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $94 | $9,53414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.
Other urology in Houston
- Arun RaiHouston$920K
- Donald GriffithHouston$732K
- Jonathan Clavell HernandezHouston$500K
- Ashish KamatHouston$481K
- Mohit KheraHouston$428K
- Ricardo GonzalezHouston$314K
- Richard LinkHouston$261K
- Steven CanfieldHouston$256K
- Kathleen KobashiHouston$159K
- Steven MaislosHouston$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.